 | Examines the market for addiction pharmacotherapies currently estimated at US$2 billion
The substance dependence field is transforming into a high-growth market opportunity. Supported by the success of Pfizer's recently launched Chantix/Champix, which is on track for blockbuster status in the smoking cessation sector, pharmacotherapies in development for alcohol, narcotic, and nicotine dependencies are poised to radically change the addiction treatment landscape in this difficult-to-treat patient population.
The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016.
The World Market for Addiction Disorders, 2009 2016: Future Therapies for Substance Dependence and Impulse Control, will introduce the reader a specialty pharmaceutical market which is positioned for high-growth based on analysis of marketed and pipeline drugs, company activities, and addiction disorder demographics. |
|
| In the US, the pharmaceutical supply chain involves the daily delivery of approximately 13 million prescription products to pharmacies, hospitals, clinics and other healthcare provider locations.
In recent years, the US government and interested parties have made increasing efforts to protect the national supply chain for medicines distribution. Since it represents the means for medicines to reach patients, any breaches in the system would be catastrophic and could affect millions of people. The system faces numerous external threats, including counterfeiting, terrorism and disruption resulting from man-made and natural disasters. Industry challenges include the dominance of 3 wholesalers, growth of mail order and the wave of pharmacy consolidation. |
|
| Critical success factors for competing in a consolidating market"2009 is set to redefine the structure and dynamics of the pharmaceutical industry in a way not seen since the year 2000"On 26th January 2009, Pfizer announced plans to acquire Wyeth for $68 billion. Pfizer’s CEO, Jeffrey B Kindler, insisted the deal would be different from the company’s earlier mega-deals involving the acquisitions of Pharmacia (2002) and Warner-Lambert (2000) – the acquisition of Wyeth would provide a broad and diversified portfolio, rather than been focused on a single product or cost-cutting. Pfizer’s strategy of growing its portfolio through a mega M&A deals follows the 2008 acquisitions of Millennium by Takeda and ImClone by Eli Lilly. |
|
| Mega-mergers and the blockbuster model have not delivered the benefits that were claimed for them. Growth in the pharmaceutical market has slowed to no more than five per cent and the world's biggest companies are growing slowly, if at all. Against that background pharmaceutical companies, large and small, are looking for new ways to do business - ways that will bring success in a difficult market. For ways to discover and deliver new drugs, to manufacture them more cost-effectively and to sell and market them more successfully. |
|
| Sales of biologics grew by 20% in 2007, far faster than sales of small molecule drugs, which grew by not much more than 5%. And the number of biologics being launched is continues to grow very rapidly. But biologics are not like small molecules: not only are they more complex to develop, test and produce, but they are more difficult to define which means that maintenance of quality together with safety and efficacy is a major challenge. |
|
| Updated, comprehensive report delivers accurate market figures and forecasts on the global cancer drug market. Contains profiles of top pharmaceutical companies in this sector."The global market for new cancer patients is set to increase from 4.0 million cases in the major cancer markets in 2007 to 4.2 million in 2012"The global cancer market has seen a continued period of rapid growth. Global sales for cancer-treating drugs increased by 13.3% in 2007, primarily driven by growth in sales of innovative drugs. Although growth rates for this market will slow due to generic competition, the market is predicted to expand to $103.9 billion by 2012, equivalent to CAGR of 9.4%.Key findings from this report: * The global cancer market grew to US$66.2 billion in 2007, a year-on-year increase of 13.3%. * This market growth in 2007 was primarily driven by growth of 44.0% in innovatives sales. * There were a total of 21 different cancer therapies generating global sales in excess of US$1 billion in 2007. * The leading company by cancer sales in 2007 was Amgen, with sales of US$11.1 billion. * The global cancer market is forecast to expand to US$103.9 billion in 2012, equivalent to a CAGR of 9.4% over the next 5 years. |
|
| An overview of Egypt, Israel, Jordan, Lebanon, Saudi Arabia & UAE“Massive growth is being forecast for the pharmaceutical and biotechnology markets of Middle Eastern states, driven by moves to liberalise national economies, the introduction of mass health insurance and the determination of the region’s governments to become self-sufficient in pharmaceuticals production.”Major Pharmaceutical Markets of the Middle East (2nd Edition) is a comprehensive report providing extensive coverage of one of the strongest emerging markets. Through quality analysis and forecasts, this unique report will allow you to identify market trends and growth potential opportunities.This best-selling report provides the necessary background information for a firm to operate in the region. |
|
| A step-by-step guide to accurately forecasting the price of generic drugs over a 3 year period“Finally. A model for predicting the price fall of generics – proven to have worked for 99% of drugs”It has long been recognised that prices paid by chemists and doctors for a generic product decline in the weeks and months after generic launch and patent expiry. But calculating how quickly this happens can often only be guessed at - until now |
|
| The new edition of this best-selling report offers insight into the manufacturing process, strategy, issues and drivers from an expert author.Manufacturing in the Global Pharmaceuticals Industry - Key drivers, company strategies and regulations (3rd ed) is the only report available that covers this crucial area of the pharmaceutical industry in such depth. The concentration in recent years on creating organisations that are market or customer-led, or research-driven has taken the focus away from the manufacturing process, although it is clear that the most successful organisations integrate all these activities to remain market leaders. |
|
| "Each day millions of patients across Europe rely on the supply chain to deliver the medicines they need"Pharmaceutical Distribution in Europe - The Emergence of Direct-to-Pharmacy Supply from URCH Publishing, is a market report that comprehensively reviews the business of medicines distribution in Europe.The traditional model of pharmaceutical supply chain in Europe is under threat as major pharmaceutical manufacturers in the UK attempt to change the way they distribute their products. The adoption of a Direct-to-pharmacy (DTP) model by some of the industry's most powerful players in the UK signifies a new trend that could spread across Europe. |
|
| "Among the 23 new pharmaceutical products approved in the first half of 2007, there were 22 small molecule pharmaceutical drugs and one monoclonal antibody."Pharmaceutical Product Approval Trends 2007: Key market benchmarks and strategic insights presents a detailed analysis of the new pharmaceutical products approved globally.The 120-page report outlines the key therapeutic markets, significant pharmaceutical entities which were approved, assesses major companies and identifies key trends and opportunities in order to help inform pharmaceutical decision-making, particularly in the areas of corporate planning, portfolio management and market forecasting. |
|
| For many years generic companies were the poor relations of the pharmaceutical industry, with modest growth rates and little or no transnational business operations. As generics companies have grown, often by acquisition, they have generally developed as international businesses. |
|
| "The global pharmaceutical market grew to US$712 billion in 2007 at a compound annual growth rate (CAGR) of 10.0% between 1999 and 2007. Year-on-year the global pharmaceutical market increased to 10.7% in 2007, largely as a result of strong sales for new innovative products and high market growth in emerging pharmaceutical markets such as China." |
|
| The global cardiovascular market is forecast to expand to US$116.3 billion in 2010, equivalent to a CAGR of 5.3% over the next five years. The slow-down in cardiovascular market growth between 2003 and 2005 is forecast to continue through to 2010. While continued changes in demographics and lifestyle will continue to drive cardiovascular sales forward, growth rates will be limited by continued patent expiries for major products and a dearth of novel therapies being introduced.Cardiovascular Pharmaceutical Market Trends, 2007 to 2010 - Key market forecasts and growth opportunities provides an in-depth analysis of the growing market for pharmaceutical treatments for cardiovascular disorders including: - Coronary heart disease- Cerebrovascular disease - Peripheral arterial disease- Rheumatic heart disease - Congenital heart disease- Deep vein thrombosis and pulmonary embolism This comprehensive report, from URCH Publishing, delivers market forecasts and overviews to help inform you in your pharmaceutical business decision-making. |
|
| The global market for drugs treating Central Nervous System (CNS) disorders has grown rapidly in recent years to reach US$55.5 billion in 2005, a year-on-year increase of 6.6%.Between 2003 and 2005, global CNS sales increased by 19% and accounted for 9.2% of total global pharmaceutical sales in 2005. Annual global CNS sales growth slowed from 11.5% in 2004 to 6.6% in 2005 as a result of generic competition for leading anti-depressant and epilepsy therapies. |
|
| The Handbook of Pharmaceutical Additives, 3rd Edition describes more than 5,300 trade name products and 4,000 generic chemicals and materials, available from worldwide manufacturers, that function as pharmaceutical additives. |
|
